Services for population genomics initiatives
Your European partner for population scale genomics
Leverage our scalable infrstructure.
Custom solutions for unique challenges
Benefit from our consultative approach to navigating complex projects with ease.
Automation
We offer streamlined, fast, stable and improved processes with our advanced automation technologies.
Scalability
Easily expand your sample volumes to according to your project with our scalable solutions.
Multiomics
Integrate diverse data types for comprehensive insights through our multiomics approach.
Local Provider
Benefit from EU standards and on site support by a trusted and well known local provider.
Highest Accreditation Level
Rest assured, our laboratory meets the highest standards of quality and reliability, accredited to ISO 15189.
Skilled Scientists
Our team of skilled scientists brings expertise and innovation to every project.
Multiomics Overview
Designed to meet the unique demands of your project
Explore all available options.
Genomics
Key Insights for Disease Genetics and Public Health
Genomics is pivotal in population health research, offering insights into disease genetics and aiding personalized medicine. Techniques like genotyping identify genetic markers for health conditions, while next-generation sequencing uncovers broader genetic variations. These tools are essential in epidemiological studies, helping to track disease trends and inform public health strategies, ultimately advancing our understanding of the genetic basis of diseases and their impact on populations.
Platforms
- Illumina
- Thermo Fisher
- MGI
- Oxford Nanopore (Long-Read)
Workflows
- Whole Genome Sequencing
- Sequencing only
- Whole exome sequencing
- Shotgun metagenomics
Epigenomics
Bridging Genetics and Environmental Factors in Disease Development
Epigenomics, exploring beyond genetic sequences to how genes are expressed, is crucial in population health studies. It helps in understanding how environmental factors and lifestyle choices influence gene expression, contributing to disease development. This field is key in unraveling the complex interplay between genetics and the environment, providing a more comprehensive picture of health and disease mechanisms, highlighting how external factors can shape genetic outcomes.
Platforms
- Oxford Nanopore (Long-Read)
- Illumina
- MGI
Workflows
- Long read on Oxford Nanopore
- Bisulphite sequencing
- Enzymatic conversion
- Illumina EPIC & MSA arrays
Transcriptomics
Exploring RNA Transcripts: Insights into Gene Regulation
Transcriptomics is a vital component in population health research, focusing on the study of RNA transcripts to understand gene expression patterns. This field has become even more relevant with the identification of over 190 RNA modifications, which add another layer of complexity to gene expression regulation. By analyzing these RNA molecules, transcriptomics provides critical insights into how genes are activated or silenced in different health conditions, offering a deeper understanding of disease mechanisms and potential therapeutic targets.
Platforms
- Oxford Nanopore (Long-Read)
- Illumina
- Thermo Fisher
- MGI
Workflows
- RNS seq
Proteomics
Bridging Genotype and Phenotype in Health Studies
Proteomics, the study of proteins, is fundamental in population health research. It delves into protein structures, functions, and interactions, providing crucial insights into various biological processes and disease mechanisms. Understanding protein dynamics helps in identifying biomarkers for diseases and potential therapeutic targets, enhancing disease diagnosis and treatment strategies. Proteomics is key in understanding the functional implications of genetic information, bridging the gap between genotype and phenotype in population health studies.
Platforms
- Olink
- Somalogic
- Illumina
Workflows
- Olink Explore HT
- Olink targetted panels
- SomaScan panels
***Early Access***
Accelerate your research with the next-generation SOMAmer Plasma Proteomics and Illuminas´s NovaSeq X Plus System
Unlock the future of Proteomics. Download the full protein list today and explore the precision of SOMAmer for breakthrough discoveries.
Genotyping
Population health screening leverages next-generation sequencing and high-throughput genotyping to identify genetic risk factors, enabling targeted interventions in large populations.
NGS
Next-generation sequencing (NGS) enables rapid and cost-effective sequencing of entire genomes, allowing for comprehensive genetic analysis and insights into disease susceptibility and treatment.
Long Read
Long-read sequencing technology provides high-resolution genomic data by accurately mapping complex regions of DNA, enhancing our understanding of structural variations and improving disease detection.
Proteomics
Proteomics uses advanced techniques like mass spectrometry to analyze protein expression and interactions, facilitating insights into disease mechanisms and potential therapeutic targets.
Technology Overview
Designed to meet the unique demands of your project
Explore all available options.
Microarrays
Genotyping by Microarrays
Population scale screening arrays combine universal genome-wide content, curated clinical research variants and QC markers.
Genome-wide multiethnic GWAS backbone
- Build on whole-genome reference data from 1000 genomes
- Global content is cross-population and population specific
Laboratory information management system
- Disease and trait associated markers (ClinVar / PharmGKB / NHGR-EBI)
- Cross-population and population specific exonic content
- HLA alleles and extended MHC region.
Quality control markers
- Sample identification / tracking, ancestry determination, stratification
NGS
Next Generation Sequencing
The midplex genotyping approach is highly accurate, robust, cost-efficient, flexible and customisable.
SNP biomarker validation
- Population screening
- Biobank screening (retrospective analysis of germline SNPs)
- Disease screening.
Accuracy and robustness
- On average > 97% successful SNP design and > 98% sample call rate
- Low DNA amounts needed (20 ng): Crude DNA extraction possible for blood, tissue and cells
- High multiplexing capabilities at low costs and fast TAT (1 – 3 weeks).
Flexibility and customisation
- Completely customized sets of SNPs (10 – 1,000)
- Additional samples can be added any time
- Flexible system allowing implementation of additional SNPs at a later stage
- Analysis of either one SNP or several SNPs per target region
Low Pass Sequencing
Next Generation Genotyping by Low Pass Sequencing
Discover biomarkers with cost-efficient “Low Pass Whole Genome Sequencing”.
Low pass whole genome sequencing
- < 10x coverage
- 150 paired-end sequencing on NovaSeq 6000
Cost-efficient alternative to WGS
- Detection of noven SNPs
- Missing genomic region can be filled by “imputation”
Ideal for large scale projects
- Population screening of a > 15.000 patient cohort from a biobank
Most relevant applications
- Genome-wide association studies (GWAS)
- Population screening
- Ancestry analysis
- Biobank profiling
- Investigation of complex diseases
Free consulting for your population genomics project
Speak to our population genomics experts about your ideas
Our team of experts can advise and assist you with all
the information on our end-to-end service offer.
References
Project Examples
Our Future Health, UK
Eurofins Genomics partners in pioneering UK health project, providing advanced genotyping for 5 million participants. Advancing precision medicine and personalised healthcare with an unwavering commitment to genomic advancements. Upholding the highest standards for quality, accuracy, and efficiency in genotyping services. Working with partners to revolutionise healthcare through genomics.
Work conducted by Eurofins Genomics:
- Genotyping will be performed on illumina custom array with 700k SNPs
- We are building a dedicated lab in UK
- The goal of the Our Future Health program is to facilitate the discovery and development of new methods of prevention, early detection and treatment of a wide range of diseases
- Today, 59% of UK citizens aged 65 years or older have two or more serious health conditions, and this statistic has been projected to reach 70% by 2035. With the recruitment of five million adult volunteers, this research program has the potential to improve the long-term health of millions of people in the UK and globally. The insights gained into links between DNA and diseases through this program will accelerate the development of innovative solutions to help people to live healthier lives for longer.
The Simpler Project, Uppsala University
The infrastructure SIMPLER consists of questionnaire data and biological samples for research on how dietary, lifestyle factors and genetics affect health, especially during the latter part of life.
Work conducted by Eurofins Genomics:
- DNA extraction of 38.000 saliva and blood samples
- Genotyping on microarrays of 40.500 samples
- The success rate (sample to genotype) has been extremely high, above 99%
- The project began in late spring 2019 and was completed on time as scheduled at the end of 2020
- Genotyping was performed on the Illumina Infinium Global Screening Array (GSA MD 3.0)
“We are very happy with Eurofins’ competence and professional approach” comments Anna-Karin Kolseth, project coordinator, SIMPLER.
Low-Pass Sequencing for "Top-20 Pharmaceutical Company"
Fast, cost-efficient and high throughput Next Generation Sequencing for Top 20 pharma client.
Sucessfully completed a few weeks time 18.000 sample cohort up to 2.500 WGS samples per week.
Work conducted by Eurofins Genomics:
- Dedicated, pro-active Consulting & Project Management
- Incl. Weekly update calls
- Tailored Quality Control reports
- Customized Data Transfers
Free consulting for your population genomics project
Speak to our population genomics experts about your ideas
Our team of experts can advise and assist you with all
the information on our end-to-end service offer.
Approved by your peers from Ancestry, Genealogy, Health & Wellness
We are a trusted population genomics brand around the globe
We cooperate with renowned organisations, ranging from small to large-scale enterprises to provide ‘best-in-class’ genomic services to both established and new, emerging consumer genomics markets. Scientists around the world recognise and trust the Eurofins brand for its reputation for quality, timeliness and efficiency. We host only industry-leading platforms for DNA extraction, genotyping, sequencing and related consumer genomics applications.
Meet our wordclass laboratories
Denmark and UK
Highly specialized laboratories are essential for conducting advanced analyses, such as NGS and proteomics, as they ensure precision, accuracy, and adherence to stringent quality standards, ultimately enhancing the reliability of diagnostic and research outcomes.
Welcome to our state-of-the-art genomics lab in Galten, Denmark, established in 2019. As the largest array laboratory in Europe, we specialize in population health through advanced automation technologies. Our cutting-edge facility is dedicated to delivering precise genomic analyses that enhance public health outcomes and support innovative research initiatives. Join us in our mission to transform healthcare through the power of genomics!
Welcome to our advanced laboratory in Milton Keynes, UK, built to meet the latest requirements for serving UK customers. Here, we conduct the largest population health studies worldwide in collaboration with OFH, utilizing cutting-edge sequencing technologies at any scale. Our commitment to innovation and excellence ensures that we provide the highest quality genomic analyses to drive impactful health solutions.
Quality you can rely on
Work with a fully certified population genomics partner
ISO 17025
Guaranteed confidentiality and integrity of testing data.
Testing results are recognised by authorities and customs, etc. for the release of pharmaceuticals and food and feed, in the case of legal implications.
ISO 15189
ISO 15189 is an international standard for medical laboratories that focuses on quality management and competence.
It requires laboratories to establish a quality management system, ensure staff competency, maintain suitable facilities and equipment, and control documents and records. The standard promotes continual improvement and emphasizes accurate, reliable test results to enhance patient safety and healthcare delivery.
GDPR
All data is stored and processed on German servers.
We do not share data with third parties.
Only necessary data is requested.
Customer data is stored using the most advanced security tools.
Customer voice
„We are very happy to work with Eurofins Genomics because it has allowed us to absorb our exponential growth in the number of samples analysed, while maintaining exceptional process quality.“
Customer voice
„Not only do they have one of the most advanced laboratories in Europe, but also the human team behind them is amazing. We look forward to continuing to grow with them.“
Your dedicated Consumer genomics Expert
Daniel Langhoff
Business Development Director
Eurofins Genomics Europe